[ 3 / biz / cgl / ck / diy / fa / ic / jp / lit / sci / vr / vt ] [ index / top / reports ] [ become a patron ] [ status ]
2023-11: Warosu is now out of extended maintenance.

/biz/ - Business & Finance

Search:


View post   

>> No.19213371 [View]
File: 2.07 MB, 1755x972, 5.png [View same] [iqdb] [saucenao] [google]
19213371

>>19213333
any link to cramer? Ive been holding for a month atleast. Avg @ 2.75

>> No.19201965 [View]
File: 2.07 MB, 1755x972, 5.png [View same] [iqdb] [saucenao] [google]
19201965

>>19201468
>5 employees
um yes, in its only operational clinic in canada. That generated 1.7milion in its first year operating. Imagine the revenue when this is on more peoples radar, like say...doctors.

Open 10 more clinics for x10 the revenue.
They have a team of dozens of scientists and doctors. That are not included in your numbers

>> No.19155715 [View]
File: 2.07 MB, 1755x972, 5.png [View same] [iqdb] [saucenao] [google]
19155715

>>19155635
Part of the team at Alt med include Roger Mcintyre. Dr. McIntyre is involved in multiple research endeavours which aim to characterize the association between mood disorders, especially cognitive function and medical comorbidity. Broadly, his work aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment. As you can see in the following slide he is incorporating the use of psilocybin or ketamine for persons with mood disorders.

Four months ago the FDA approved esketamine, a one off molecule of ketamine. The only clinic operating in the states is owned by SHRM. The only clinics operating in Canada, are also owned by Altmed (SHRM)

>> No.19125451 [View]
File: 2.07 MB, 1755x972, 5.png [View same] [iqdb] [saucenao] [google]
19125451

Part of the team at Alt med include Roger Mcintyre. Dr. McIntyre is involved in multiple research endeavours which aim to characterize the association between mood disorders, especially cognitive function and medical comorbidity. Broadly, his work aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment. As you can see in the following slide he is incorporating the use of psilocybin or ketamine for persons with mood disorders.

Navigation
View posts[+24][+48][+96]